The Translational Genomics Research Institute

Phoenix, AZ, United States

The Translational Genomics Research Institute

Phoenix, AZ, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Dignity Health and The Translational Genomics Research Institute | Date: 2017-03-31

The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.


Patent
The Translational Genomics Research Institute | Date: 2017-04-18

The invention encompasses methods and kits used to detect biomarkers that may be used to predict disease outcome in adrenocortical carcinoma patients.


Patent
The Translational Genomics Research Institute | Date: 2017-04-03

Among other aspects provided herein is a method describing the use of Single Nucleotide Polymorphism (SNP) genotyping microarrays to resolve whether genetic material (such as genomic DNA) derived from a particular individual is present in a genetic material mixture (such as a complex genomic DNA mixture) is disclosed. Furthermore, it is demonstrated that the identification of the presence of genetic material (such as genomic DNA) of specific individuals within a series of complex genomic mixtures is possible.


Patent
The Translational Genomics Research Institute | Date: 2017-02-23

Methods useful in the prediction and detection of a triple negative cancer subtype using biomarkers are provided herein.


Patent
The Translational Genomics Research Institute and British Columbia Cancer Agency Branch | Date: 2015-03-23

The present invention relates compositions, methods and kits for characterizing the type of and screening for the existence or predisposition for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The invention also relates to a method of treating a mammalian subject having SCCOHT or a predisposition for SCCOHT.


Patent
The Translational Genomics Research Institute | Date: 2016-06-20

Methods of tests that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer that are likely or unlikely to respond to treatment with BTK inhibitors; methods of treating subjects based on identification of the subjects as likely to respond to treatment with BTK inhibitors; therapeutic targets for cancers, particularly cancers with inactivated DPC4 gene or protein; methods of screening of new therapeutic agents using the target; pharmaceutical composition comprising BTK inhibitors, such as PCI-32765 or derivatives thereof, for cancer treatment; and kits that facilitate the performance of the methods are disclosed.


Patent
The Translational Genomics Research Institute | Date: 2016-07-07

The invention encompasses methods used in the sensitization and treatment of cancer based upon the expression of SGEF.


Patent
The Translational Genomics Research Institute and Northern Arizona University | Date: 2016-07-20

Embodiments of the invention provide a method of detecting one or more strains of Klebsiella pneumoniae. The method may include forming a plurality of mixtures for nucleic amplification. The method can include amplification of specific sequences within the K. pneumonia genome that can provide definitive information to distinguish between one or more types or strains of K. pneumonia.


Patent
The Translational Genomics Research Institute and Mayo Foundation For Medical Education And Research | Date: 2016-03-14

The invention encompasses methods of treating a patient with cancer, such as glioblastoma. The methods may include the administration of one or more pharmaceutical compositions that are capable of inhibiting TROY to treat the patient with cancer.


Patent
The Translational Genomics Research Institute and University of Washington | Date: 2016-03-31

Diagnostic and therapeutic applications for endometrial cancer are described. The diagnostic and therapeutic applications are based on certain activation mutations in the FGFR2 gene and its expression products. The present invention is directed to nucleotide sequences, amino acid sequences, probes, and primers related to FGFR2 activation mutants and kits comprising these mutants to diagnosis and classify endometrial cancer in a subject.

Loading The Translational Genomics Research Institute collaborators
Loading The Translational Genomics Research Institute collaborators